tbuckley/cabot-search huggingface dataset:
TOXIC PSYCHOSIS RESULTING FROM PENICILLIN
Authors: C L KLINE, L S HIGHSMITH
Journal: Annals of Internal Medicine (1948)

Case Reports1 May 1948TOXIC PSYCHOSIS RESULTING FROM PENICILLINCARL L. KLINE, M.D., LARUE S. HIGHSMITH, M.D.CARL L. KLINE, M.D.Search for more papers by this author, LARUE S. HIGHSMITH, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-28-5-1057 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough a variety of allergic reactions have been described following the therapeutic use of penicillin,1 no instance of toxic psychosis resulting from this drug has, to our knowledge, previously been reported.CASE REPORTThe patient was an 18 year old white, single, female college student. She first received penicillin for an upper respiratory illness on March 13, 1947, at which time she received a total of 480,000 units intramuscularly in 36 hours without any type of reaction. On March 18, 1947, she was readmitted to the school infirmary with an otitis media, and penicillin was again prescribed. She received a...Bibliography1. HOLDEN EM: Allergic reaction to penicillin, New Eng. Jr. Med., 1947, ccxxxvi, 796-798. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Columbia, Missouri*Received for publication June 23, 1947. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPENICILLINAuthors' replyToward an Interface of Mental and Physical Health Phenomena in Geriatrics: Clinical Findings and QuestionsDrug-induced Psychoses and their Relationship to SchizophreniaElevated Plasma Procaine Concentrations after Administration of Procaine Penicillin GDie symptomatischen PsychosenREFERENCESACUTE PSYCHOTIC REACTION AFTER INJECTION OF PROCAINE PENICILLIN.ACUTE PSYCHOTIC REACTION AFTER INJECTION OF PROCAINE PENICILLIN. A Report of 33 CasesDie symptomatischen PsychosenDer Einfluß von Vitamin P auf die experimentelle Penicillin-IntoxikationGruppe der ChemotherapeuticaComplications of antibiotic therapyALLERGY, ANTIBIOTICS AND CHEMOTHERAPEUTICSA controlled study of the effect of oral penicillin G in the treatment of non-specific upper respiratory infectionsThe toxic psychoses and allied statesRHEUMATISM AND ARTHRITIS REVIEW OF AMERICAN AND ENGLISH LITERATURE OF RECENT YEARS (TENTH RHEUMATISM REVIEW)* Part IIWILLIAM D. ROBINSON, M.D., F.A.C.P., EDWARD W. BOLAND, M.D., F.A.C.P., JOSEPH J. BUNIM, M.D., F.A.C.P., DARRELL C. CRAIN, M.D., F.A.C.P., EPHRAIM P. ENGLEMAN, M.D., F.A.C.P., WALLACE GRAHAM, M.D., F.R.C.P. (C), L. MAXWELL LOCKIE, M.D., F.A.C.P., MAX M. MONTGOMERY, M.D., F.A.C.P., CHARLES RAGAN, M.D., F.A.C.P., MARIAN W. ROPES, M.D., F.A.C.P., EDWARD F. ROSENBERG, M.D., F.A.C.P., CHARLEY J. SMYTH, M.D.Syphilis 1 May 1948Volume 28, Issue 5Page: 1057-1058KeywordsAllergy and immunologyDrugsOtitis mediaPenicillinPsychosesPulmonary diseases ePublished: 1 December 2008 Issue Published: 1 May 1948 PDF downloadLoading ...
Why don't probiotics work?
Authors: Bert Jan Korte, S. Mechiel Korte
Journal: Behavioral and Brain Sciences (2019)

Abstract The conclusions reached by Hooks et al. urge the field to investigate the complex multipathway interactions between the microbiome and the gut-brain axis to understand the potential causal relationships involved. Claims in the field of microbiota-gut-brain research remain problematic without appropriate controls and adequate statistical power. A crucial question that follows from the authors' extensive review is: “Why don't probiotics work?”
Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 ’START-A’ study
Authors: M. Talpaz, J. F. Apperley, D. W. Kim, R. T. Silver, E. O. Bullorsky, S. Cheng, M. Iyer, F. Guilhot
Journal: Journal of Clinical Oncology (2006)

6526 Background: Dasatinib (D) (BMS-354825) is an oral multi-targeted kinase inhibitor with preliminary evidence of efficacy in a previously reported phase I study. START A is an open-label study of dasatinib in AP-CML pts who were imatinib resistant (IM-R) or imatinib intolerant (IM-I). Methods: A total of 192 pts were enrolled between December 2004 and Jun 2005 in 39 centers worldwide. Dasatinib was given orally at 70 mg twice daily (BID). Dose escalations to 100 mg BID were allowed for poor initial response and reductions to 50 or 40 mg BID for persistent toxicity. Evaluations were weekly blood counts and monthly bone marrow evaluation including cytogenetics. The primary endpoint was major confirmed (maintained at least 4 weeks) hematologic response (MaHR) in IM-R pts. Results: The first 107 pts (99 IM-R, 8 IM-I) with at least 6 months of follow-up are currently reported; there were 55 males/52 females; median age 57 years (range 23–86); median time from diagnosis of CML 90.9 months. Prior therapy included IM&gt;600 mg/day in 63 (59%) pts, interferon in 80 (75%) pts. Major cytogenetic response (MCyR) to prior IM was seen in 34 (32%) pts. 56 pts had Bcr-Abl kinase domain mutations. Median duration of therapy was 5.5 months. MaHR was documented in 63 (59%) pts (95% CI: 49–68) with complete hematologic response in 35 (33%) and no evidence of leukemia in 28 (26%). In IM-R pts, the MaHR rate was 59%. MCyR was documented in 33 (32%) pts (95% CI: 22.9–41.6); complete in 23 (22%), partial in 10 (10%). MaHR were seen in pts with Bcr-Abl mutations and in pts who never responded to IM. Molecular response analysis is ongoing. There were 15 disease progressions including one loss of MaHR. Myelosuppression was significant with grade 3–4 thrombocytopenia and neutropenia in 79% and 69% of pts, respectively. Non-hematologic toxicities were generally mild to moderate. The most frequent were diarrhea (46%), peripheral edema (27%), pleural effusion (16%), rash (8%), and GI hemorrhage (7%). Conclusions: Dasatinib was very effective in IM-R pts with AP-CML with high rates of durable MaHR and MCyR. Data on all 192 pts will be presented at the meeting. [Table: see text]
Toward more reliable stability measurements in stance: recommendations for number of measurements, foot position and feedback -- a cross-sectional study among servicemen
Authors: Saskia Maria Theresia van der Heijden, Maarten Reinders Prins, Peter van der Wurff
Journal: Military Medical Research (2019)

In the military, insufficient postural stability is a risk factor for developing lower extremity injuries. Postural stability training programs are effective in preventing these injuries. However, an objective method for the measurement of postural stability in servicemen is lacking. The primary objective of this study was to assess the influence of the number of repetitions, different foot positions and real-time visual feedback on postural stability, as well as their effects on the intrasession reliability of postural stability measurements in servicemen. The secondary objective was to assess the concurrent validity of the measurements.Twenty healthy servicemen between 20 and 50 years of age and in active duty were eligible for this quantitative, cross-sectional study. The measurements took place on a force plate, measuring the mean velocity of the center of pressure. The participants were asked to stand as still as possible in three different foot positions (wide stance, small stance, and on one leg), five times each for 45 s each time, and the measurements were performed with and without real-time visual feedback.We observed a significant main effect of foot position (P < 0.001), but not of visual feedback (P = 0.119) or repetition number (P = 0.915). Postural stability decreased in the more challenging foot positions. The ICC estimates varied from 0.809 (one repetition in wide stance) to 0.985 (five repetitions on one leg). The common variance (R2) between different foot positions without feedback varied between 0.008 (wide stance) and 0.412.To yield reliable data, wide-stance measurements should be conducted three times, and small-stance measurements and measurements on one leg should be conducted two times. The scores of a measurement in a particular foot position cannot predict the scores of measurements in other foot positions.
Association of US Medical Marijuana Laws With Nonmedical Prescription Opioid Use and Prescription Opioid Use Disorder
Authors: Luis E. Segura, Christine M. Mauro, Natalie S. Levy, Nicole Khauli, Morgan M. Philbin, Pia M. Mauro, Silvia S. Martins
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Between 1997 and 2017, the United States saw increases in nonmedical prescription opioid use and its consequences, as well as changes in marijuana policies. Ecological-level research hypothesized that medical marijuana legalization may reduce prescription opioid use by allowing medical marijuana as an alternative. <h3>Objectives</h3> To investigate the association of state-level medical marijuana law enactment with individual-level nonmedical prescription opioid use and prescription opioid use disorder among prescription opioid users and to determine whether these outcomes varied by age and racial/ethnic groups. <h3>Design, Setting, and Participants</h3> This cross-sectional study used restricted data on 627 000 individuals aged 12 years and older from the 2004 to 2014 National Survey on Drug Use and Health, a population-based survey representative of the civilian population of the United States. Analyses were completed from March 2018 to May 2018. <h3>Exposures</h3> Time-varying indicator of state-level medical marijuana law enactment (0 = never law enactment, 1 = before law enactment, and 2 = after law enactment). <h3>Main Outcomes and Measures</h3> Past-year nonmedical prescription opioid use and prescription opioid use disorder among prescription opioid users. Odds ratios of nonmedical prescription opioid use and prescription opioid use disorder comparing the period before and after law enactment were presented overall, by age and racial/ethnic group, and adjusted for individual- and state-level confounders. <h3>Results</h3> The study sample included 627 000 participants (51.51% female; 9.88% aged 12-17 years, 13.30% aged 18-25 years, 14.30% aged 26-34 years, 25.02% aged 35-49 years, and 37.50% aged ≥50 years; the racial/ethnic distribution was 66.97% non-Hispanic white, 11.83% non-Hispanic black, 14.47% Hispanic, and 6.73% other). Screening and interview response rates were 82% to 91% and 71% to 77%, respectively. Overall, there were small changes in nonmedical prescription opioid use prevalence after medical marijuana law enactment (4.32% to 4.86%; adjusted odds ratio, 1.13; 95% CI, 1.06-1.20). Prescription opioid use disorder prevalence among prescription opioid users decreased slightly after law enactment, but the change was not statistically significant (15.41% to 14.76%; adjusted odds ratio, 0.95; 95% CI, 0.81-1.11). Outcomes were similar when stratified by age and race/ethnicity. <h3>Conclusions and Relevance</h3> This study found little evidence of an association between medical marijuana law enactment and nonmedical prescription opioid use or prescription opioid use disorder among prescription opioid users. Further research should disentangle the potential mechanisms through which medical marijuana laws may reduce opioid-related harm.
Abstract 358: First Trimester Human Umbilical Cord Perivascular Cells (FTM HUCPVCs) Maintain High Expression Levels of Angiogenic Factors and Have Superior Pro-angiogenic Effects on Endothelial Networks When Compared to Term HUCPVCs and BMSCs in an ex-vivo Rat Aortic Ring Assay
Authors: Farwah Iqbal, Peter Szaraz, Shlomit Kenigsberg, Andree Gauthier-Fisher, Clifford Librach
Journal: Circulation Research (2016)

Introduction: Features of an ideal cell type, that would be conducive to vascular regeneration include (1) expression of pro-angiogenic genes (2) secretion of factors that promote developing or regenerating vasculature, and (3) maintenance of pro-angiogenic properties in the microvascular niche. Hypothesis: FTM HUCPVCs, a young rich source of mesenchymal stromal-like cells (MSCs) are ideal candidates for vascular regeneration due to their high expression of pro-angiogenic factors. Methods: The paracrine angiogenic potential of 3 types of MSCs was evaluated and compared using ex vivo tissue culture of rat aortic rings. Aorta sections were embedded into Matrigel™, cells were added to transwell membranes (pore=0.1μm, EBM 2% FBS) and combined with aortic rings (Day 0). Radial network growth and total loop formation were monitored by microscopy. Endothelial networks were quantified by ImageJ TM software. p values were calculated using ANOVA. (N=3 experiments, n=3 replicates). At day 7, the MSCs were isolated from transwells, human cytokine gene expression levels were measured using human growth factor profiler qPCR array (Qiagen, normalizers: GAPDH, βACT). Ct&gt;35 considered negligible. Results: In the transwell aortic ring assay, FTM HUCPVCs induced significantly greater network growths when compared to term HUCPVCs (p≤0.0001), BMSCs (p≤0.0001) and untreated rings (p≤0.05). Quantification of network loop formation showed that FTM HUCPVCs induced greater numbers of closed loops when compared to term HUCPVCs (p≤0.0001), BMSCs (p≤0.0001) and untreated networks (p≤0.0001). Human growth factor qPCR array showed a high expression of angiogenic factors (Ct&lt;25 cycle) both at day0 and day7 of co-culture, including BMP1, GDNF, MDK, NRG1, PDGFc, VEGFa, and VEGFc. Most cytokine expression levels were maintained up to 7 days in co-culture with 1 gene upregulated (BMP6 ΔCt&gt;3), and 3 downregulated genes (FGF19, FGF9, NRTN ΔCt&gt;3) at day 7 when compared to day 1. Conclusion: Compared to older sources of MSCs, FTM HUCPVCs promote developing endothelial networks in vitro via paracrine mechanisms and maintain the high expression of pro-angiogenic factors when cultures with endothelial cells.
Applying the Guidelines for Primary Hyperparathyroidism
Authors: Kelly Wentworth, Dolores Shoback
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 18663: Detection of Bacterial Device Infection of Cardiac Devices in a Rodent Model Using a Novel Pet Imaging Probe
Authors: Kiyoko Takemiya, Wone Woo Seo, Xinghai Ning, Daiana Weiss, Giji Joseph, Jane S Titterington, Jonathon A Nye, Niren Murthy, Mark M Goodman, W. Robert Taylor
Journal: Circulation (2013)

Background: Implantable cardiac devices improve prognosis and quality of life in cardiac patients, but there are problems that stem from device infection. There is often difficulty in making a definitive diagnosis of device infections. To this end, we have developed a new approach to specifically detect bacteria using a novel PET imaging probe. Maltohexaose is taken up by bacteria via the maltodextrin transport pathway and is internalized as a major source of glucose. Mammalian tissues do not possess this transporter. In this study, we evaluated whether maltohexaose labeled with fluorine-18 (F-18 FMH) is useful as a PET tracer to detect bacterial device infection in a rat model. Methods and results: We implanted surgical grade stainless steel device mock-ups in Sprague-Dawley rats. Methicillin sensitive Staphylococcus aureus (MSSA) in exponential growth phase was diluted to 1 X 10 6 CFU/ml. In the device infection group, rats were injected with 0.1ml (1 X 10 5 CFU) of MSSA around the mock-ups on post-operative day four. Two days later, rats were injected with F-18 FMH and were scanned with micro PET/CT. Infected devices showed a very avid uptake of tracer compared to the control (not infected) devices. The ratio of the signal in the region of interest (ROI) around the mock-up area and normal skin area was measured. The ratio of ROI in the device infection group was significantly increased compared to that in the control group that had the device but no injected bacteria. (2.34 ± 0.09 vs 1.79 ± 0.06, respectively. P&lt;0.05, each n=4) In micro PET/CT imaging with the conventional tracer, fluorine-18-fluorodeoxyglucose, there was no significant change in the ratio of ROI between in the device infection group and in the control group. (2.21±0.12 vs 2.03±0.21, respectively. Each n=4) Conclusion: F-18 FMH shows great promise to be a potential tracer in PET imaging for the specific diagnosis of bacterial infections of implanted cardiovascular devices.
Incidence, severity, and etiology of treatment-related lymphopenia in patients with stage III non-small cell lung cancer (NSCLC).
Authors: Jian Li Campian, Xiaobu Ye, Craig Hooker, Malcolm Brock, Stuart A. Grossman
Journal: Journal of Clinical Oncology (2012)

e17552 Background: Severe treatment-related lymphopenia (TRL) is associated with shorter survival in patients with glioblastoma and pancreatic cancer treated with concurrent chemotherapy and radiation (chemo/RT). This retrospective study sought to determine if patients with stage III NSCLC develop TRL and if this results from chemotherapy or radiation. Methods: Patients selected for this retrospective analysis had newly diagnosed stage III NSCLC, Karnofsky performance status &gt;60, and chemo/RT and follow-up blood counts at Johns Hopkins Hospital. Patients were divided into those who received neoadjuvant chemotherapy followed by chemo/RT and those who received only chemo/RT. Serial lymphocyte counts were analyzed. Results: Forty-six adults met the above eligibility criteria. Their median age was 62 years (range 43-79), 65% were female, 74% were stage IIIA and 26% were IIIB, 72% had adenocarcinoma, and 68% were poorly differentiated. Surgery included pneumonectomy (7%), lobectomy (43%), wedge resection (7%), or biopsy (43%). Twenty patients received neoadjuvant chemotherapy consisting of 2 cycles of taxol/carboplatin (85%) or gemcitabine/carboplatin (15%). Their mean total lymphocyte count (TLC) prior to chemotherapy was 1416 cells/mm 3 (SD 899). TLC remained unchanged after the neoadjuvant chemotherapy (mean 1519, SD 553). These patients then received concurrent chemo/RT (mean dose 58.4 Gy). TLC fell 68% at two months from a mean of 1519 (SD 553) to 490 (SD 305) (p&lt;0.00001) with 55% having TLC ≤500 cells/mm 3 . The remaining 26 patients received only concurrent chemo/RT. Their initial TLCs were normal (mean 1807, SD 644) but two months later had fallen by 70% (mean 545, SD 397) (p&lt;0.00001) with 54% having TLC ≤500 cells/mm 3 . Reductions in TLCs occurred irrespective of the chemotherapy administered with RT. Conclusions: TLCs are normal in patients with newly diagnosed stage III NSCLC and are unaffected by 2 cycles of neoadjuvant chemotherapy. However, with the addition of radiation TLCs drop in ~50% of patients to levels associated with severe immunosuppression. Further studies are needed to determine if this is associated with reduced survival as reported in other malignancies.
Anaesthetist is charged with injecting partner with “noxious substance” that left her in critical condition
Authors: Clare Dyer
Journal: BMJ (2019)

An anaesthetist has been sent to the crown court on charges that he injected his partner, a nurse, with a “noxious substance” that left her in a critical condition.

The nurse, Kelly Wilson, 31, has been admitted to a hospital intensive care unit after being injected with unspecified controlled drugs during what the prosecution alleges was a “ritual.” Hossam Metwally, an anaesthetist …
Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study
Authors: Julie Kanter, Abdullah Kutlar, Darla Liles, Rodolfo Cançado, Andreas Bruederle, Michael Shi, Zewen Zhu, Kenneth I Ataga
Journal: Blood (2017)
Outcomes of tbo-filgrastim, filgrastim-sndz or filgrastim for mobilization in patients undergoing an autologous hematopoietic stem cell transplant: A single center experience.
Authors: Klodiana Neme, David Henkin, Nancy Mikulandric, Meredith Grycki, Angela Michael, Cassandra Smith, Josephine Emole
Journal: Journal of Clinical Oncology (2019)

e19000 Background: Studies have reported that use of filgrastim (G) or any biosimilar result in similar stem cell yield during hematopoietic stem cell mobilization, but little is known on the effect of these biosimilars on length of hospitalization for the transplant procedure, engraftment, and long term survival of autologous hematopoietic stem cell transplant (HSCT) patients. Beginning January 2017, the Henry Ford Cancer Institute (HFCI) began utilizing tbo-filgrastim (TBO) and filgrastim-sndz (SNDZ) as part of mobilization. This study was conducted to evaluate transplant specific outcomes in HSCT patients comparing biosimilar and reference filgrastim products. Methods: This study retrospectively evaluated all patients treated at HFCI who received G-CSF based mobilization for HSCT between 1/2017 and 11/2018. Patient-, mobilization- and transplant specific variables were collected and analyzed. Results: A total of 113 patients underwent stem cell mobilization followed by collection and autologous HSCT. Of the 73 patients analyzed, 62% had a diagnosis of Multiple Myeloma (MM), 22% had Non-Hodgkin Lymphoma (NHL). Approximately 45% of patients received TBO, 44% received G and remainder received SNDZ. The percentage of patients who proceeded to HSCT was 86%. There was no difference in adequate CD34+ yield among the three G-CSF products (P = 0.074). There was no difference in mobilization associated complications including bone pain and thrombocytopenia. Plerixafor use was similar among the groups (P = 0.55). Actual CD34+ (P = 0.31) and the number of apheresis sessions required to collect an adequate CD34+ yield (P = 0.30) were not different among the groups. No significant differences were noted in time to neutrophil (P = 0.96) or platelet engraftment (P = 0.91) and hospital length of stay (P = 0.78). We found similar rates of infection, febrile neutropenia, and mucositis among the three groups. Relapse rates were also similar among the groups. Conclusions: In our institution transplant related outcomes were similar among patients who received TBO, SNDZ, and G as part of their pre-transplant mobilization protocol.